Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.
He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), Korro Bio, Triplet Therapeutics and Translate Bio (NASDAQ: TBIO). Jean-François also serves on the boards of F-star, Ikena Oncology and Spero Therapeutics (NASDAQ: SPRO).
His prior investments include Adnexus, ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL) and NxStage (NASDAQ: NXTM).
Jean-François is a member of the Partners Healthcare Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.